Annual financial results as of 31 December, 2021
29/04/2022 – AB Science reports its revenues for the year 2021 and provides an update on its activities
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19
28/04/2022 – AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)